<DOC>
	<DOC>NCT02163720</DOC>
	<brief_summary>The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.</brief_summary>
	<brief_title>Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)</brief_title>
	<detailed_description>Population : Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal with platinum-sensitive recurrent witch it was decided to initiate a treatment with trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients aged 18 years and over, Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive Yondelis®Caelyx® in relapse platinumsensitive Patients should be informed of the study orally and should not have any objection their data to be processed Patient participation in a clinical trial Patient nonaffiliated to a social security scheme.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian tube or primary peritoneal</keyword>
	<keyword>relapse</keyword>
	<keyword>platinum-sensitive</keyword>
	<keyword>Yondelis®-Caelyx®</keyword>
</DOC>